Latest News on Piramal Pharma
Piramal Pharma Enhances Biologics Production Capacity to Address Growing Industry Requirements – geneonline.com
Piramal Pharma, a leading global pharmaceutical company, has announced the expansion of its biologics manufacturing infrastructure to cater to the growing demand for biologic therapies. The company has invested in upgrading its facilities and capabilities to enhance its biologics manufacturing services, including process development, scale-up, and commercial production.
The expansion is part of Piramal Pharma’s strategy to strengthen its position as a trusted partner for biopharmaceutical companies, providing end-to-end services for the development and manufacture of biologics. The company’s biologics business has been growing rapidly, driven by the increasing demand for biologic therapies to treat a range of diseases, including cancer, autoimmune disorders, and genetic disorders.
Piramal Pharma’s biologics manufacturing infrastructure is designed to meet the highest standards of quality, safety, and regulatory compliance. The company’s facilities are equipped with state-of-the-art equipment and technology, including single-use bioreactors, chromatography systems, and fill-finish lines. The company has also implemented advanced process control systems and quality management systems to ensure that its biologics products meet the required standards of quality and purity.
The expansion of Piramal Pharma’s biologics manufacturing infrastructure includes the addition of new production lines, laboratories, and process development facilities. The company has also hired a team of experienced biologics manufacturing professionals, including process engineers, quality assurance specialists, and regulatory experts. This team will work closely with clients to develop and manufacture biologics products that meet their specific needs and requirements.
Piramal Pharma’s biologics manufacturing services include cell line development, process development, scale-up, and commercial production. The company also offers a range of analytical and testing services, including bioanalytical testing, immunogenicity testing, and stability testing. The company’s biologics products are designed to meet the needs of a range of therapeutic areas, including oncology, immunology, and rare diseases.
The expansion of Piramal Pharma’s biologics manufacturing infrastructure is expected to have a significant impact on the biopharmaceutical industry, enabling the company to meet the growing demand for biologic therapies and providing biopharmaceutical companies with a trusted partner for the development and manufacture of biologics. With its enhanced capabilities and infrastructure, Piramal Pharma is well-positioned to play a key role in the development of new biologic therapies and the treatment of a range of diseases. Overall, the expansion is a significant step forward for Piramal Pharma and is expected to drive growth and innovation in the biopharmaceutical industry.
Piramal Pharma Limited Boosts Biologics Production Capabilities to Boost Drug Development Efficiency – geneonline.com
Piramal Pharma Limited, a leading global pharmaceutical company, has announced its strategic investment in advanced biologics manufacturing to enhance drug development efficiency. This move is expected to strengthen the company’s capabilities in the biopharmaceutical sector and enable it to better serve its clients and partners.
The investment will focus on developing and implementing cutting-edge technologies and processes in biologics manufacturing, including cell line development, fermentation, and purification. By leveraging these advanced technologies, Piramal Pharma aims to improve the efficiency, productivity, and quality of its biologics manufacturing operations.
The company’s decision to invest in biologics manufacturing is driven by the growing demand for biologic therapies, which are increasingly being used to treat a range of diseases, including cancer, autoimmune disorders, and rare genetic disorders. Biologics are complex molecules that require specialized manufacturing processes, and Piramal Pharma’s investment is expected to enable it to meet the growing demand for these therapies.
The advanced biologics manufacturing capabilities will be integrated into Piramal Pharma’s existing facilities, which will enable the company to offer a seamless and integrated service to its clients, from early-stage development to commercial manufacturing. The company’s expertise in biologics manufacturing will also enable it to support the development of novel therapies, including gene therapies and cell therapies.
Piramal Pharma’s investment in biologics manufacturing is also expected to enhance its competitiveness in the global pharmaceutical market. The company’s advanced manufacturing capabilities will enable it to differentiate itself from its competitors and establish itself as a leading player in the biopharmaceutical sector.
The investment in biologics manufacturing is part of Piramal Pharma’s broader strategy to enhance its capabilities in drug development and manufacturing. The company has also been investing in other areas, including small molecule manufacturing, pharmaceutical services, and pharmaceutical research and development.
Overall, Piramal Pharma’s investment in advanced biologics manufacturing is expected to have a positive impact on the company’s growth and competitiveness in the global pharmaceutical market. The company’s enhanced capabilities in biologics manufacturing will enable it to better serve its clients and partners, and support the development of novel therapies that can improve human health. With its strong expertise in biologics manufacturing, Piramal Pharma is well-positioned to capitalize on the growing demand for biologic therapies and establish itself as a leading player in the biopharmaceutical sector.
Piramal Pharma Limited Enhances Biologics Production Capacity to Address Increasing Market Needs – geneonline.com
Piramal Pharma Limited, a leading global pharmaceutical company, has announced the expansion of its biologics manufacturing infrastructure to meet the growing industry demand. The company has invested in new facilities and upgraded existing ones to enhance its capabilities in biologics manufacturing, process development, and analytical services.
The expansion is a strategic move to capitalize on the increasing demand for biologics, which are expected to drive the growth of the pharmaceutical industry in the coming years. Biologics are complex molecules that require specialized manufacturing facilities and expertise, and Piramal Pharma Limited is well-positioned to cater to this demand with its state-of-the-art infrastructure and team of experienced professionals.
The company’s biologics manufacturing facility is designed to meet the highest standards of quality and compliance, with features such as isolator technology, single-use bioreactors, and advanced process control systems. The facility has the capability to manufacture a range of biologics, including monoclonal antibodies, proteins, and vaccines, and can support clients from early-stage development to commercial-scale production.
Piramal Pharma Limited’s expansion plans include the addition of new laboratories, offices, and manufacturing suites, as well as the upgrade of existing equipment and systems. The company has also invested in the latest technologies, such as advanced chromatography and filtration systems, to enhance its biologics manufacturing capabilities.
The company’s biologics business has experienced significant growth in recent years, driven by the increasing demand for biologics and the company’s expertise in this area. Piramal Pharma Limited has a strong track record of delivering high-quality biologics products and services to its clients, and the expansion of its manufacturing infrastructure is expected to further strengthen its position in the market.
The expansion is also expected to create new job opportunities and drive economic growth in the region. Piramal Pharma Limited has a strong commitment to social responsibility and sustainability, and the company is working to minimize the environmental impact of its operations and promote social and economic development in the communities it serves.
Overall, Piramal Pharma Limited’s expansion of its biologics manufacturing infrastructure is a significant development that is expected to drive growth and innovation in the pharmaceutical industry. With its state-of-the-art facilities, experienced team, and commitment to quality and compliance, the company is well-positioned to meet the growing demand for biologics and deliver high-quality products and services to its clients.
Piramal Pharma Boosts Biologics Production Capacity to Accelerate New Medicine Development – geneonline.com
Piramal Pharma, a leading global pharmaceutical company, has announced the expansion of its biologics manufacturing infrastructure to enhance its drug development capabilities. This strategic move is aimed at strengthening the company’s position in the biopharmaceutical market and providing innovative solutions to patients worldwide.
The expansion includes the addition of new biologics manufacturing facilities, which will increase the company’s production capacity and enable it to cater to the growing demand for biologics. The new facilities will be equipped with state-of-the-art technology and will adhere to the highest standards of quality and regulatory compliance. The company has invested significantly in the expansion, demonstrating its commitment to delivering high-quality biologics to patients.
Piramal Pharma’s biologics manufacturing infrastructure will provide a comprehensive range of services, including cell line development, process development, and commercial manufacturing. The company’s expertise in biologics manufacturing will enable it to support clients across various stages of drug development, from early-stage research to commercial production.
The expansion of Piramal Pharma’s biologics manufacturing infrastructure is expected to have a positive impact on the pharmaceutical industry. It will provide access to high-quality biologics manufacturing services, enabling pharmaceutical companies to bring new treatments to market more quickly and efficiently. This, in turn, will benefit patients worldwide, who will have access to innovative and life-changing therapies.
The company’s investment in biologics manufacturing is also a testament to the growing importance of biologics in the pharmaceutical industry. Biologics have revolutionized the treatment of various diseases, including cancer, autoimmune disorders, and rare genetic disorders. As the demand for biologics continues to grow, Piramal Pharma is well-positioned to support the development and manufacturing of these complex therapies.
In conclusion, Piramal Pharma’s expansion of its biologics manufacturing infrastructure is a significant development in the pharmaceutical industry. The company’s commitment to delivering high-quality biologics manufacturing services will enable pharmaceutical companies to bring new treatments to market, ultimately benefiting patients worldwide. With its state-of-the-art facilities and expertise in biologics manufacturing, Piramal Pharma is poised to play a leading role in the development and manufacturing of biologics, shaping the future of the pharmaceutical industry.
Overall, Piramal Pharma’s investment in biologics manufacturing infrastructure reflects the company’s dedication to innovation, quality, and patient-centricity. As the pharmaceutical industry continues to evolve, Piramal Pharma is well-positioned to address the growing demand for biologics and make a meaningful impact on the lives of patients worldwide.
Piramal Pharma supports Women’s Wellbeing with the launch of its i-pill Daily Awareness Initiative
Piramal Consumer Healthcare has launched a new campaign for its i-pill Daily product, which aims to promote women’s health, dignity, and informed choice. The campaign highlights the importance of choosing the right brand, especially in a category where substitution is common and purchases are often made with hesitation. The goal is to encourage consumers to ask boldly, insist clearly, and choose confidently, rather than settling for a substitute due to discomfort or haste.
The campaign is set in a black-and-white style and aims to tackle the barrier of lack of insistence on the right brand at the moment of purchase. The film cleverly draws attention to the outdated discomfort surrounding the buying experience and flips the narrative by urging viewers to ask questions, assert their agency, and choose a trusted brand like i-pill Daily.
According to Nandini Piramal, Chairperson of Piramal Pharma Limited, every woman deserves access to healthcare that is safe, reliable, and respectful of her choices. The campaign reminds women that their health is too important to be left to chance or compromise and encourages them to choose what’s best for them.
Menaka Menon, President and Managing Partner of DDB Mudra Group, commented that the campaign aims to tackle the problem of consumers ending up with a substitute product due to social conditioning and embarrassment around the purchase of a contraceptive product. The campaign plays up the shift in society towards women exercising their discretion and choice, and contrasts it with the meek acceptance typically associated with such decisions in the past.
The campaign is backed by Piramal Pharma’s strong record in women’s wellness and is recognized as one of India’s Most Trusted Brands by Marksmen. It marks a strategic shift from generic awareness to informed, quality-first decisions. The film will be supported across digital platforms, including YouTube and Instagram, and will be amplified on television in select priority markets.
Overall, the campaign aims to empower women to make informed choices about their reproductive health and to choose a trusted brand like i-pill Daily. By encouraging consumers to ask boldly and insist clearly, the campaign hopes to reverse the trend of substitution and promote a culture of confidence and assertiveness around women’s health.
Stock Market Updates for Piramal Pharma
Recent Updates
Piramal Pharma’s i-pill Daily campaign empowers women to make educated decisions about their reproductive health.
Piramal Consumer Healthcare has launched a new campaign for its emergency contraceptive pill, i-pill Daily, with the aim of empowering women to take control of their reproductive health and make informed choices. The campaign highlights the importance of insisting on the right brand at the point of purchase, as many women often end up with a substitute due to discomfort and haste during the buying experience. The campaign encourages women to “ask boldly, insist clearly, and choose confidently” when it comes to their reproductive health.
The film, shot in black and white, tackles the outdated discomfort surrounding the purchase of contraceptive products and urges viewers to assert their agency and choose a trusted brand like i-pill Daily. The campaign is built on the idea that every woman deserves access to healthcare that is safe, reliable, and respectful of her choices. Nandini Piramal, Chairperson of Piramal Pharma Limited, stated that the campaign is a reminder to women that their health is too important to be left to chance or compromise.
The campaign aims to address the issue of substitution, where women often end up with a different brand due to social conditioning and embarrassment. Menaka Menon, President and Managing Partner of DDB Mudra Group, commented that the campaign plays on the shift in society towards women exercising their discretion and choice, and contrasts it with the meek acceptance typically associated with such decisions in the past.
The film will be supported across digital platforms, including YouTube and Instagram, and will be amplified on television in select priority markets. The campaign is a significant step towards promoting women’s health, dignity, and informed choice, and encouraging women to take control of their reproductive health. By emphasizing the importance of choosing a trusted brand like i-pill Daily, the campaign aims to convert salience into sales at the point of purchase and promote a more empowered and informed approach to women’s healthcare.
Unlocking the Emerging Opportunities in India’s Pharmaceutical Industry
The Indian pharmaceutical sector has demonstrated robust growth over the past year, driven by a new trade agreement with the European Union that reduces tariffs on key drug exports. This agreement is expected to enhance India’s position as a global supplier of generic medicines, leading to increased trade volume and job creation. The sector has shown positive momentum in the short term, reflecting a steady rise in investor confidence. Analysts project substantial upside potential for various companies operating in this space.
Several top companies in the sector have been identified as having strong upside potential. Cohance Lifesciences Limited, a technology-driven contract development and manufacturing organization, has a target price of Rs. 1400.00, indicating an upside potential of 33%. Piramal Pharma Limited, a global pharmaceutical company, has a target price of Rs. 271.00, reflecting an upside potential of 32%. Natco Pharma Limited, a vertically integrated pharmaceutical company, has a target price of Rs. 1090.00, indicating an upside potential of 28%.
Other companies with strong upside potential include Aurobindo Pharma Limited, which has a target price of Rs. 1470.00, reflecting an upside potential of 23%, and Blue Jet Healthcare Limited, which has a target price of Rs. 943.00, indicating an upside potential of 19%. Zydus Lifesciences Limited, a global life sciences company, has a target price of Rs. 1040.00, reflecting an upside potential of 18%.
Overall, the outlook for the Indian pharmaceutical sector remains positive, driven by the new trade agreement with the European Union and the growth potential of various companies operating in the space. Analysts recommend a strong buy for Cohance Lifesciences and Piramal Pharma, a buy for Aurobindo Pharma and Blue Jet Healthcare, and a hold for Natco Pharma and Zydus Lifesciences.
The financial performance of these companies has been strong, with many reporting significant year-on-year sales growth. However, some companies have seen a decline in profit after tax (PAT) due to various factors. Despite this, the long-term implications of the trade agreement and the growth potential of the sector are expected to drive growth and innovation in the Indian pharmaceutical industry.
Uncertainty in US Policy Hinders Pharmaceutical Investment Decisions
The pharmaceutical industry is experiencing a period of uncertainty due to recent US policy directives, which are causing global pharmaceutical companies to delay major outsourcing decisions. Piramal Pharma, a contract development and manufacturing organization (CDMO), is taking a cautious approach and waiting for clarity on US policy before making any major commitments. Despite this, the company remains optimistic about its future prospects due to its geographically diverse network, which spans the US, UK, and India.
Piramal Pharma’s chairperson, Nandini Piramal, stated that decision-making has been prolonged, with clients holding off on commitments until there is more certainty. However, the company has seen an increase in requests for proposals (RFPs) and is confident that its network will position it well once the landscape stabilizes. The company anticipates muted growth in the short term, but expects a strong rebound by FY27 as the environment stabilizes and client commitments resume.
In FY25, Piramal Pharma reported a robust performance, with revenue increasing by 12% to ₹9,151 crore. The CDMO business contributed significantly, with revenue increasing by 15% year-on-year. The company also reported a 17% EBITDA margin and a fivefold increase in net profits. Looking ahead, Piramal Pharma is investing $90 million to expand two of its manufacturing facilities in the US, which aligns with its long-term goal of becoming a $2 billion revenue company by FY2030.
The US policy directives, introduced under President Donald Trump’s administration, have created a ripple of hesitation across the pharmaceutical sector. The directives call for domestic drug manufacturing and global price alignment for branded drugs, which has made it harder for CDMOs to secure new business from global pharma clients. However, Piramal Pharma is well-positioned to navigate this uncertainty due to its diverse network and strategic investments in the US. With a strong track record of performance and a clear roadmap for growth, Piramal Pharma is confident that it will emerge stronger once the industry uncertainty subsides.
Piramal Pharma receives regulatory approval to market Neoatricon in the UK, paving the way for its availability in the market.
Piramal Pharma Limited, in collaboration with BrePco Biopharma Ltd, has received regulatory approval from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for Naeoatricon, a new pediatric-strength dopamine hydrochloride infusion for the treatment of hypotension in neonates, infants, and children. Piramal Critical Care (PCC) has secured commercialization rights for the EU, UK, and Norway, and will manage the product in these regions.
Naeoatricon is an age-appropriate, ready-to-use, sterile solution for infusion of dopamine hydrochloride, available in two concentrations: 1.5mg/mL in a 30 mL vial and 4.5mg/mL in a 50 mL vial. Until now, there has been no approved dopamine hydrochloride formulation specifically indicated for use in neonates, infants, or children, with off-label use being a common practice.
The approval of Naeoatricon aims to address this gap, ensuring accurate dosing, minimizing the risk of under or overdosing, and reducing preparation time in neonatal and pediatric intensive care units (NICU & PICU), thus enabling faster intervention in emergency settings. With this approval, Naeoatricon sets a new standard in pediatric critical care.
The availability of Naeoatricon is a significant development in the field of pediatrics, as it provides a safe and reliable solution for healthcare professionals and parents. It aims to improve patient outcomes and optimize treatment in neonatal and pediatric critical care units, ultimately leading to better health outcomes for the most vulnerable patients.
Piramal Pharma sets its sights on ambitious $2 billion revenue target by FY30, poised for a decade of exponential growth.
Piramal Pharma, a multi-faceted pharmaceutical company, is poised to achieve its goal of reaching $2 billion in revenues and becoming one of the top 10 companies in its addressable markets by 2030, according to Chairperson Nandini Piramal. The company has been growing at a rate of 10-15% across its various business verticals over the past few years. In the last nine months of FY25, Piramal Pharma reported a growth of 14% compared to the same period in FY24, with revenues of ₹6,397 crore.
One of the company’s main growth drivers is its contract development and manufacturing (CDMO) business, which accounted for 58% of its revenues in FY24. The CDMO business has seen an 18% growth in the last three quarters and aims to grow to $1.2 billion with an EBITDA margin of 25% by 2030. The company’s CDMO business focuses on differentiated services and on-patent molecules, with a strong pipeline of over 150 projects across multiple phases, including 34% in Phase 3 clinical trials. Piramal expects at least half of these products to become commercial and offer long-term manufacturing opportunities for large pharma and emerging biotechs.
The company’s other business verticals, including complex hospital generics, India consumer healthcare, and a joint venture with Abbvie for ophthalmic products, are also performing well. With its global presence and diversified portfolio, Piramal Pharma is well-positioned to achieve its ambitious goals and solidify its position in the pharmaceutical industry.